• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Reveromycin A

Reveromycin A

Product ID R1985
Cas No. 134615-37-5
Purity ≥98%
Product Unit SizeCostQuantityStock
100 µg $324.50 In stock
5 x 100 µg $1,297.90 Please Inquire
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Reveromycin A is an osteoclast-targeting antibiotic compound that exhibits anti-resorptive and antifungal activities. In animal models of juvenile Paget’s disease, reveromycin A inhibits bone resorption and normalizes bone turnover and formation. Reveromycin A inhibits isoleucyl-tRNA synthase, preventing protein synthesis in osteoclasts; this induces apoptosis and prevents resorption in vivo. Additionally, reveromycin A inhibits bone metastasis by lung cancer cells.

Product Info

Cas No.

134615-37-5

Purity

≥98%

Formula

C36H52O11

Formula Wt.

660.79

Chemical Name

Butanedioic acid, mono(3-butyl-8-(9-carboxy-6- hydroxy-3,7-dimethyl-2,4,8-nonatrienyl)-2-(4-carboxy-3-methyl-1,3-butadienyl)-9-methyl-1,7-dioxaspiro(5.5)undec-3-yl) ester

IUPAC Name

(2E,5S,6E,8E)-10-[(2S,3R,6S,8R,9S)-3-butyl-2-[(1E, 3E)-4-carboxy-3-methylbuta-1, 3-dienyl]-3-(3-carboxypropanoyloxy)-9-methyl-1, 7-dioxaspiro[5.5]undecan-8-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

Melting Point

95°C

Solubility

Soluble in DMF, DMSO, ethanol, ethyl acetate or methanol.

Appearance

Tan Lyophilisate

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

R1985 MSDS PDF

Info Sheet

R1985 Info Sheet PDF

References

Yabumoto T, Miyazawa K, Tabuchi M, et al. Stabilization of tooth movement by administration of reveromycin A to osteoprotegerin-deficient knockout mice. Am J Orthod Dentofacial Orthop. 2013 Sep;144(3):368-80. PMID: 23992809.

Hiraoka K, Zenmyo M, Watari K, et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci. 2008 Aug;99(8):1595-602. PMID: 18754872.

Woo JT, Kawatani M, Kato M, et al. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4729-34. PMID: 16537392.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • P1622

    Pefloxacin Methanesulfonate Dihydrate

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • C0261

    Captopril

    ACE inhibitor.

    ≥98%
  • E6398

    EPZ-5676

    DOT1L HMT inhibitor.

    ≥98%
  • S291333

    Shikonin

    Natural anthraquinone derivative

    ≥98%
  • L5750

    Lomeguatrib

    MGMT inhibitor.

    ≥98%
  • N8604

    NVP-BGT226

    PI3K and mTOR inhibitor.

    ≥98%
  • N7200

    NS-11394

    GABA-A α5/3/2 positive modulator.

    ≥98%
  • A064766

    ABT 639

    T-type calcium channel blocker

    ≥99%
  • H1794

    Hexamethonium Bromide Hydrate

    Non-depolarizing NMJ blocker; nAChR antagonist....

    ≥98%
  • N0163

    2-(1,8-Naphthyridin-2-yl)phenol

    Naphthalene; indirect STAT1 agonist.

    ≥98%
  • I5206

    INCB 28060 Hydrochloride Hydrate

    c-MET inhibitor.

    ≥98%
  • O6845

    Orlistat

    Fatty acid synthase inhibitor.

    ≥98%
  • D1760

    3-Acetyl-deoxynivalenol

    Type A trichothecene mycotoxin produced by Fusa...

    ≥98%
  • C5662

    Copper Bis-3,5-diisopropylsalicylate

    Antioxidant.

    ≥97%
  • E7433

    Etidronate Disodium

    Bisphosphonate, chelating agent.

    ≥98%
  • I6804

    Irbesartan

    PPARγ agonist, AT1 inhibitor.

    ≥98%
  • P691320

    PRI-724

    Wnt/beta-catenin/CBP inhibitor

    ≥98%
  • O783720

    OTS-964

    Inhibitor of T-lymphokine-activated killer cell...

    ≥98%
  • G0044

    Galantide

    Peptide; galanin antagonist.

    ≥95%
  • E7657

    Etoposide

    Podophyllotoxin derivative; topoisomerase II in...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only